Y-90 Radioembolization, also known as Selective Internal Radiation Therapy (SIRT), uses millions of microscopic, radioactive beads to fight liver cancer from the inside out.
About this scan
Common Indications for Y-90
This treatment may be considered for selected patients with:
- Primary liver cancer or tumors that have spread to the liver.
- Liver tumors that cannot be removed surgically.
How is it different from normal radiation?
Traditional radiation is beamed from outside the body, which can damage healthy tissue. Y-90 delivers the radiation directly into the tumor's blood supply. The tiny beads get stuck inside the tumor, delivering a very high dose of radiation from the inside over the course of about two weeks.
Why do I need a "mapping" scan first?
Y-90 is a two-step process. About a month before your actual treatment, you must have a "mapping arteriogram." During this dry run, the doctor maps out the exact blood vessels feeding the tumor. Because the radioactive beads must stay in the liver, the doctor checks to see if any stray blood vessels connect the liver to your stomach or lungs. If they find any, they will block those stray vessels to ensure the radiation only goes exactly where it is supposed to.
Before your appointment
What happens during the actual treatment?
Once your mapping is complete, the treatment day is very straightforward. The doctor navigates a tube into your liver artery and releases the radioactive Yttrium-90 beads. You will be relaxed and sleepy, and there is very little discomfort.
Safety and special situations
What are the important limitations and safety checks?
Interventional radiology is minimally invasive, but it is not risk-free and is not automatically safer or more effective than surgery, endoscopy, medicines, or observation for every patient. Technical success does not always produce symptom relief or cure disease, and repeat treatment or another approach may be needed. Suitability depends on anatomy, disease severity, comorbidities, imaging, local expertise, and the alternatives available.
Risks vary by procedure and may include pain, bleeding, infection, contrast reaction, kidney injury, radiation exposure, vessel or organ injury, clotting, device movement or blockage, sedation complications, treatment failure, and an unplanned operation or admission. Tissue sampling can be nondiagnostic and requires pathology; tumor treatments require oncology follow-up. The consent discussion should cover the patient-specific benefits, material risks, alternatives, and what happens if the procedure cannot be completed.
Preparation is individualized. Give the team a complete list of anticoagulants, antiplatelet drugs, diabetes medicines, supplements, allergies, kidney problems, pregnancy possibility, and prior contrast reactions. Do not stop a blood thinner or diabetes medicine on your own: the procedural team and prescribing clinician must balance bleeding against thrombosis or metabolic risk and provide exact written instructions. Fasting, laboratory tests, antibiotics, sedation, escort, admission, and aftercare differ by procedure.
Sources and summary
Sources and further reading
Conclusion
Y-90 radioembolization can deliver a high liver-targeted radiation dose, but mapping reduces rather than eliminates nontarget exposure. Radiation pneumonitis, gastrointestinal ulceration, liver injury, biliary complications, fatigue, treatment failure, and delayed effects are possible; dosimetry and oncology follow-up are essential.